Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CPK 850

Next Previous
Drug Profile

CPK 850

Alternative Names: CPK850; CPK850 Gene Therapy; scAAV8-pRLBP1(short)-hRLBP1 vector; scAAV8-RLBP1

Latest Information Update: 06 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Retinitis pigmentosa

Most Recent Events

  • 06 Jan 2023 Phase II trial in Retinitis pigmentosa is still ongoing in Sweden (NCT03374657)
  • 24 Jul 2020 Phase II trial in Retinitis pigmentosa is still ongoing in Sweden (NCT03374657)
  • 22 Jul 2020 Novartis plans to submit first regulatory application for Retinitis pigmentosa in or after 2026 (Novartis pipeline, February 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top